The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.

A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. Reuters/Phil Noble A closely watched immune system-boosting drug cocktail from Britain’s AstraZeneca shows promise in advanced lung cancer, despite adverse side effects in a number of patients. Researchers said on Wednesday that the combination of the experimental drugs […]

(Reuters Health) – In 2013, mammogram and colorectal cancer screening rates had stalled and Pap tests were on the decline, with many eligible U.S. adults not getting the recommended tests, according to a new report. Among people who should be regularly screened for breast, colon and cervical cancer according to current guidelines, many are not […]

A simple daily vitamin may help prevent the most common types of skin cancer in people at high risk of the disease, according to new research from Australia. A study conducted at the University of Sydney found that nicotinamide, a form of vitamin B3, reduced by 23 percent the incidence of new, non-melanoma skin cancers […]

  A personalized treatment targeting a patient’s individual genetic makeup helped cure more children with a rare form of kidney cancer, researchers said on Wednesday.  The findings, based on two studies led by Dr. David Dix of the British Columbia Children’s Hospital in Vancouver, were released ahead of the American College of Clinical Oncology meeting […]

  The addition of an experimental Bristol-Myers Squibb biotech medicine to standard therapy for patients whose multiple myeloma has relapsed led to longer remissions and cut the risk of death over standard treatment alone, according to data from a late stage study. The drug, elotuzumab, which is being developed in collaboration with AbbVie, extended the […]